Immupharma (IMM)

 

Latest News

London Investor Evening

RNS Number: 9140E Immupharma PLC 15 February 2018 15 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") London Investor Evening Monday 26 February 2018 @ 6pm ImmuPharma PLC (LSE: IMM) , specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman, will be presenting at an invest...

Holding(s) in Company

RNS Number: 4832E Immupharma PLC 09 February 2018 9 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Holding in Company ImmuPharma PLC (LSE: IMM) , the specialist drug discovery and development company, announces that on 8 February 2018 it received notification that Alto Invest no longer holds a notifiable interest in the Com...

Holding(s) in Company

RNS Number: 1713E Immupharma PLC 07 February 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma p...

Holding(s) in Company

RNS Number: 8539D Immupharma PLC 05 February 2018 5 February 2018 ImmuPharma PLC ("ImmuPharma" or the "Company") Notification of Major Interest Lanstead Increases Holding to over 5% ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, has received notification that Lanstead Capital LP ("Lanstead") has confir...

All News

DateHeadlineSource
15-02-18London Investor EveningRNS
09-02-18Holding(s) in CompanyRNS
07-02-18Holding(s) in CompanyRNS
05-02-18Holding(s) in CompanyRNS
02-02-18Six AIM pharma shares on verge of breakthroughInteractive Investor
31-01-18Holding(s) in CompanyRNS
24-01-18ImmuPharma raises £10mStockMarketWire
24-01-18Successful Placing to Raise ?10 MillionRNS
18-01-18Completion of LupuzorT Pivotal Phase III StudyRNS
21-12-17ImmuPharma completes dosing in Lupuzor study StockMarketWire
21-12-17Grant of OptionsRNS
21-12-17Last patient completes dosing in LupuzorT TrialRNS
12-12-17Broker Forecast - finnCap issues a broker note on ImmuPharma PLCStockMarketWire
28-11-17Holding(s) in CompanyRNS
24-11-17Grant of OptionsRNS
02-11-17Lupuzor trial on track, says ImmuPharma StockMarketWire
02-11-17Update on LupuzorT Pivotal Phase III StudyRNS
16-10-17Holding(s) in CompanyRNS
04-10-17ImmuPharma completes sharing agreement with Lanstead StockMarketWire
04-10-17Completion of Lanstead Sharing AgreementRNS
27-09-17ImmuPharma revenues riseStockMarketWire
27-09-17Interim ResultsRNS
26-09-17Preparation of Lupuzor'sT Regulatory SubmissionsRNS
21-09-17Update on LupuzorT Pivotal Phase III StudyRNS
19-09-17ImmuPharma schedules interims StockMarketWire
19-09-17Notification of Interim ResultsRNS
18-08-17AIM Rule 17 NoticeRNS
12-07-17Grant of OptionsRNS
30-06-17Result of AGMRNS
30-06-17Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
30-06-17Update on LupuzorT Pivotal Phase III StudyRNS
07-06-17Annual Report & Notice of AGMRNS
01-06-17ImmuPharma losses widenStockMarketWire
01-06-17Final ResultsRNS
22-05-17Notification of Full Year ResultsRNS
17-05-17Lupuzor study on track, says ImmuPharma StockMarketWire
17-05-17Update on Lupuzor Phase III StudyRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
31-03-17New Employee Share Option Plan & Grant of OptionsRNS
24-03-17ImmuPharma to present at Master Investor ShowRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account